Open access

Rett Syndrome

Written By

Daniela Zahorakova

Submitted: 10 July 2012 Published: 17 April 2013

DOI: 10.5772/55020

From the Edited Volume

Chromatin Remodelling

Edited by Danuta Radzioch

Chapter metrics overview

3,009 Chapter Downloads

View Full Metrics

1. Introduction

Defects in epigenetic mechanisms can give rise to several neurological and behavioral phenotypes. Rett syndrome (MIM 312750) is a pervasive neurodevelopmental disorder that is primarily caused by mutations in a gene encoding methyl-CpG-binding protein 2. The functions of the protein are related to DNA methylation, a key epigenetic mechanism that plays a critical role in gene silencing through chromatin remodeling. Rett syndrome was the first human disorder in which a link between epigenetic modification and neuronal dysfunction was discovered. In this chapter, the clinical features and the molecular pathology of Rett syndrome will be discussed.

1.1. History

Rett syndrome was first recognized by the Viennese pediatrician Andreas Rett. In 1965, he observed two girls sitting on their mothers’ laps in his waiting room. Both girls were profoundly intellectually disabled and were continually wringing their hands in the same unusual manner. Dr. Rett recollected seeing such behavior in previous patients and searched for their files with his secretary. They found several girls with a similar developmental history and clinical features. He realized that these symptoms constituted something other than cerebral palsy, which was the usual designation at the time. In 1966, Dr. Rett published the first description of the disorder that now bears his name [1]. His paper, however, remained unnoticed by the medical community until the 1980s, when Swedish child neurologist Bengt Hagberg with colleagues published the same clinical findings and named the disorder Rett syndrome [2]. Later, diagnostic criteria were proposed [3], and Rett syndrome became recognized worldwide by pediatricians, neurologists, geneticists, and neuroscientists. Despite great effort, the genetic cause of the disorder was not determined until more than 30 years after the first clinical account. In 1999, mutations within the methyl-CpG-binding protein 2 gene (MECP2) were identified in patients with Rett syndrome [4], which became a turning point in Rett syndrome research. This discovery allowed the molecular confirmation of clinical cases and contributed to amendments of the diagnostic criteria [5]. Most importantly, this finding started an extensive investigation into the molecular mechanisms that underlie the pathology of Rett syndrome.

1.2. Occurence

The estimated prevalence of Rett syndrome is 1:10,000 females by the age of 12 years old [6] with no specific ethnic or geographical preference. Rett syndrome is one of the leading genetic causes of profound mental retardation in females, second only to Down syndrome [7]. Male cases are very rare, and their phenotypic manifestations are different from those observed in girls with Rett syndrome.


2. Clinical aspects of Rett syndrome

2.1. Symptoms and stages

Rett syndrome, in its classic form, begins to manifest in early childhood and is characterized by neurodevelopmental regression that severely affects motor, cognitive, and communications skills.

Prenatal and perinatal periods are usually normal. Affected girls appear to develop normally during the first 6 to 18 months of life and seem to achieve appropriate developmental milestones. Nevertheless, retrospective analyses of home videos often show that, even during this period, affected female infants display some suboptimal development. This underdevelopment may include subtle motor and behavioral abnormalities, as well as hypotonia and feeding problems. General mobility and eye-hand coordination may be inadequate, and an excess of repetitive hand patting can be observed even during the first year of life. However, the overall developmental pattern is not obviously disturbed. The child is usually quiet and placid, and the parents often describe the child as “very good” [1, 8-11]. The characteristic clinical features appear successively over several stages, forming a distinctive disease progression pattern (Figure 1).

Figure 1.

Onset and progression of Rett syndrome [12]

Stage I: Early onset stagnation (age of onset: 6-18 months). Psychomotor development begins to slow, but the general developmental pattern is not significantly abnormal. The deceleration of head growth (which eventually leads to microcephaly), growth retardation, and weight loss occur in most patients. The child is delayed or ceases in the acquisition of skills. Although babbling and new words may appear, language skills usually remain poor. A girl with Rett syndrome may become irritable and restless, and she may begin to display some autistic features, such as emotional withdrawal and indifference to the surrounding environment [11, 13, 14]

Stage II: Developmental regression (age of onset: 1-4 years). This stage may occur over a period of days to weeks and is characterized by a rapid reduction or loss of acquired skills, especially purposeful hand use, speech, and interpersonal contact [15]. In some patients, the decline of motor and communicative performances is more gradual. Interest in people and objects is diminished, but eye contact may be preserved [11]. Voluntary hand use, such as grasping and reaching out for toys, is replaced with repetitive stereotypic hand movements, the hallmark of Rett syndrome. Patterns consisting of wringing, hand washing, mouthing, clapping, rubbing, squeezing, and other hand automatisms occur during waking hours [1, 16, 17]. Febrile seizures are often present, and epileptic paroxysms occur in most patients [18, 19]. The severity of seizures can vary, ranging from relatively mild or easily controlled by medication to severe drug-resistant episodes [20]. Irregular breathing patterns, such as episodes of hyperventilation, breath holding, and aerophagia, usually develop toward the end of the regression period. Panting, spitting, and hypersalivation are also frequent symptoms [8, 21].

Stage III: Pseudostationary period (age of onset: 4-7 years, after stage II). This stage can last for years or decades and is characterized by a relative stabilization of the disorder course. Patients may recover some skills, which were lost during the regression stage. Patients can become more joyful and sociable, and they may use eye pointing as a typical way to communicate and to express their needs. Some patients may even learn new words and use simple phrases in a meaningful way. Nevertheless, they continue to suffer from gross cognitive impairments [14]. Despite improved eye contact and non-verbal communication ability, the loss of motor functions further progresses in this stage. Stereotypic hand movements become prominent, as do breathing irregularities. Many patients develop scoliosis, which is often rapidly progressive and eventually requires surgical treatment. Cold feet and lower limbs, with or without color and atrophic changes, are also common. These conditions occur due to poor perfusion, which is a consequence of altered autonomic control. Sleeping patterns are often disturbed and are characterized by frequent nighttime waking and daytime sleeping. Unexplained night laughing, sudden agitation and crying spells may also be present [11].

Stage IV: Late motor deterioration (age of onset: 5-15 years, after stage III). Non-verbal communication and social skills continue to improve gradually. Despite persistent serious cognitive impairment, older patients with Rett syndrome are usually, in contrast to patients with childhood autism, sociable and pleasant with others [22]. Seizures become less frequent and less severe, and stereotypic hand movements become less intense. However, motor deterioration continues with age. Most patients, who previously could walk, become nonambulatory and wheelchair-dependent. Decreased mobility leads to pronounced muscle wasting and rigidity, and, at older ages, the patients often develop Parkinsonian features [11, 23, 24].

Females with Rett syndrome often survive into adulthood and older age, but their life expectancy is less than that of the healthy population. The estimated annual death rate from Rett syndrome is 1.2%. Approximately 25% of these deaths are sudden and they may occur due to autonomic nervous system disturbances or cardiac abnormalities [25-27].

Many other features are associated with Rett syndrome, but they are not considered diagnostic. The patients are generally small for their age [28], which may be due to poor self-feeding abilities and problems with chewing and swallowing. They often suffer from gastroesophageal reflux and bloating. Decreased intestinal motility often results in severe constipation. Electroencephalogram results tend to be abnormal but without any clear diagnostic pattern. A prolonged QTc interval is observed in many patients and presents a risk for cardiac arrhythmia [26].

2.2. Rett syndrome variants

At least five atypical variants have been delineated in addition to classic Rett syndrome. These variants do not have all of the diagnostic features, and they are either milder or more severe than the classic form.

The most common atypical variant of Rett syndrome is “forme fruste”. This mild variant is characterized by a protracted clinical course with partially preserved communication skills and gross motor functions. Other neurological abnormalities that are typical for Rett syndrome are more subtle and can be easily overlooked in this variant [30]. The mild forms of Rett syndrome also include the late regression variant, which manifests in patients of preschool or early school age [30], and the preserved speech variant (also called the Zappella variant) in which patients have preserved language skills and normal head sizes [31].

Severe variants include the early-onset seizure variant (the Hanefeld variant) with the onset of seizures before the age of 6 months [32] and the congenital variant, which is rare and lacks the early period of normal psychomotor development [33]. The Hanefeld variant is often caused by mutations in the CDKL5 gene [34], and most cases of the congenital variant are related to mutations in the FOXG1 gene [35]. These genetic abnormalities raise the question of whether these variants are separate clinical entities, different from MECP2-related Rett syndrome [11].

2.3. Diagnostic criteria

Despite a known genetic cause, Rett syndrome remains a clinical diagnosis. Its diagnosis is based on several well-defined criteria (Table 1), which were revised several times over the past few decades, most recently in 2010 [29].

Consider Rett syndrome diagnosis when postnatal deceleration of head growth is observed
Required for classic Rett syndrome
1. A period of regression followed by recovery or stabilization
2. All main and all exclusive criteria
3. Supportive criteria are not required, although often present in classic Rett syndrome
Required for atypical or variant Rett syndrome
1. A period of regression followed by recovery or stabilization
2. At least 2 of 4 main criteria
3. 5 out 11 supportive criteria
Main criteria
1. Partial or complete loss of acquired purposeful hand skills
2. Partial of complete loss of acquired spoken language
3. Gait abnormalities: impaired ability (dyspraxia) or absence of ability (apraxia)
4. Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing and washing/rubbing automatisms
Exclusion criteria for classic Rett syndrome
1. Brain injury secondary to trauma (perinatally or postnatally), neurometabolic disease or severe infection that cause neurological problems
2. Grossly abnormal psychomotor development in the first 6 months of life
Supportive criteria for atypical or variant Rett syndrome
1. Breathing disturbances when awake (hyperventilation, breath-holding, forced expulsion of air or saliva, air swallowing)
2. Bruxism when awake (grinding or clenching of the teeth)
3. Impaired sleep pattern
4. Abnormal muscle tone
5. Peripheral vasomotor disturbances
6. Scoliosis/kyphosis
7. Growth retardation
8. Small cold hands and feet
9. Inappropriate laughing/screaming spells
10. Diminished sensitivity to pain
11. Intense eye communication and eye-pointing behavior

Table 1.

Diagnostic criteria for Rett syndrome [29]


3. The genetics of Rett syndrome

3.1. Mapping of the causative gene

The mode of inheritance of Rett syndrome was difficult to identify because more than 99% of the cases are sporadic, and the patients rarely reproduce. Therefore, the traditional genome-wide linkage analysis was not an applicable method for mapping the disease locus. The lack of males manifesting the classic Rett syndrome phenotype together with the occurrence of families with affected half-sisters suggested an X-linked dominant inheritance with lethality in hemizygous males [2, 36]. Focused exclusion mapping of the X chromosome in available familial cases was used to narrow down the candidate region, and the subsequent analysis of candidate genes in the patients finally revealed disease-causing mutations in the MECP2 gene [4].

3.2. MECP2 gene

The MECP2 gene (MIM 300005) is located on Xq28 and undergoes X chromosome inactivation (XCI) in females [37, 38]. The gene spans approximately 76 kb and consists of four exons, which encode methyl-CpG-binding protein 2 (MeCP2). Alternative splicing of exon 2 and several polyadenylation signals in a conserved and unusually long 3’ untranslated region (3’UTR) give rise to eight different transcripts regulated in a tissue-specific and developmental stage-specific manner [39-42]. For example, the shortest transcript (1.8 kb) is predominant in adult muscles, heart, blood, and liver. The longest transcript (10.2 kb) occurs at the highest levels in the brain [41, 42]. The unique expression patterns of each transcript suggest a specific biological significance, such as a role in mRNA stability, nuclear export, folding, and sub-cellular localization, thus affecting the levels of the resulting protein [39]. The longest transcript also has one of the longest 3’ UTR tails in the human genome (8.5 kb), with several blocks of highly conserved residues between the human and mouse genomes. These findings argue in favor of a potential regulatory role of the 3’ UTR of the MECP2 gene [43].

3.3. MECP2 mutations

Mutations in the MECP2 gene are identified in 90-95% of classic Rett syndrome patients [4, 44]. Because only the coding region and the adjacent non-coding parts of the gene are routinely analyzed, it is highly probable that mutations in more remote regulatory elements are responsible for the rest of the cases. The frequency of MECP2 mutations in patients with atypical Rett syndrome variants varies considerably between studies. However, the frequency is generally lower (only 20-70% of patients have MECP2 mutations) than in the classic form [44-46], suggesting that mutations of regulatory elements or other genes are involved more often in atypical Rett syndrome than in the classic Rett syndrome. The identification of CDKL5 mutations in the Hanefeld variant and FOXG1 mutations in the congenital variant strongly support the latter idea.

According to the Human Gene Mutation Database [47], more than 550 mutations have been identified in the MECP2 gene in patients with Rett syndrome. The spectrum of mutations is heterogeneous, including missense and nonsense mutations, deletions, insertions, duplications, splice-site mutations, and large deletions of several exons or the entire MECP2 gene. More than 99% of the mutations occur de novo and mostly originate on the paternal X chromosome, which explains the high occurrence of Rett syndrome in the female gender [4, 48, 49]. Familial cases of Rett syndrome (mostly affected sisters or maternal half-sisters) are very rare. MECP2 mutations in these patients are inherited from an asymptomatic or very mildly affected mother, who carries a somatic mutation, but does not manifest the full pathogenic phenotype due to favorable XCI pattern [50, 51]. Another explanation for transmission of a MECP2 mutation to the next generation is a germline mosaicism for a mutation. It is suggested when the MECP2 mutation identified in several affected children is not present in somatic cells of their parents [51, 52].

The majority of point mutations in the MECP2 gene are C>T transitions, presumably resulting from the spontaneous deamination of methylated cytosines [53]. The mutations are scattered throughout the coding sequence and splice sites, with the exception of exon 2. The eight most common mutations, which are also C>T transitions, account for approximately 70% of the Rett syndrome cases. Approximately 10% of cases are due to deletions, which are mostly clustered in the terminal segment of the coding region [12].

3.4. MECP2 mutations in males and other disorders

Mutations in the MECP2 gene have long been considered lethal in hemizygous males, and Rett syndrome has been assumed to be exclusively a female disorder. More recently, MECP2 mutations were not only identified in males but also in females with phenotypes different from Rett syndrome. MECP2-related disorders thus represent a broad spectrum of phenotypes in both genders.

The estimated frequency of MECP2 mutations in boys with mental retardation is 1.3-1.7% [54]. Typical Rett syndrome features have been observed almost exclusively in boys with Klinefelter syndrome (47,XXY) [55] or somatic mosaicism for a MECP2 mutation [56, 57]. Other phenotypes include severe congenital encephalopathy with death in the first years of life [58-60] and mild to severe intellectual disability with or without various neurological and psychiatric symptoms [54, 61]. The most common MECP2 mutations detected in males are duplications of the whole MECP2 gene (and usually genes in its vicinity). This finding indicates that, besides the lack, an overabundance of fully functional MeCP2 protein is also harmful to the CNS. MECP2 duplication syndrome is usually very mild or does not manifest in females. In boys, this syndrome is characterized by infantile hypotonia, severe mental retardation, loss of speech, recurrent respiratory infections, seizures, and spasticity [62-64].

In females, MECP2 mutations have been detected in patients with mild mental retardation, learning disabilities or autism [65, 66]. More severe cases include severe mental retardation with seizures and Angelman-like syndrome [67, 68].

3.5. MeCP2 protein

The MeCP2 protein is ubiquitously expressed, but it is particularly abundant in the brain [41, 69]. The protein levels are low during embryogenesis, but they progressively increase during postnatal neuronal maturation and synaptogenesis [70-75]. High expression of MeCP2 in mature neurons implies its involvement in postmitotic neuronal functions, such as the modulation of neuronal activity and plasticity [12].

MeCP2 occurs in two isoforms that arise from alternative splicing of exon 2, and they differ only by their N-termini (Figure 2). MeCP2 e1 (498 amino acids), generated by exons 1, 3, and 4, is the dominant MeCP2 isoform in the brain [76-78]. The MeCP2 e2 isoform (486 amino acids) is encoded by exons 2, 3, and 4. Both isoforms were initially assumed to be functionally equivalent, but recent observations imply that additional isoform-specific functions may exist. This idea is strongly supported by the fact that no mutations in exon 2 have been found in Rett syndrome patients, which contrasts with the finding of identified mutations in exon 1. Thus, defects in MeCP2 e2 may lead to non-Rett phenotypes or fatally affect embryo viability [79, 80].

Figure 2.

MECP2 gene structure and the isoforms MeCP2 e1 and MeCP2 e2 with different N-termini due to alternative splicing of exon 2 and different translation start sites.

Apart from different N-terminal regions, both isoforms share the same amino acid sequence, including at least three functional domains and two nuclear localization signals (Figure 2). The methyl-CpG-binding domain (MBD) (amino acids 78-162) mediates binding to symmetrically methylated CpG dinucleotides [81, 82], with a preference for CpGs with adjacent A/T-rich motifs [83]. The MBD also binds to unmethylated four-way DNA junctions, which suggests the role of MeCP2 in higher-order chromatin interactions [84]. The transcriptional repression domain (TRD) (amino acids 207-310) interacts with numerous proteins, such as co-repressor factors and histone deacetylases, HDAC1 and HDAC2. The nuclear localization signals (NLS) (amino acids 173-193 and 255-271) mediate transportation of the protein into the nucleus [85]. The C-terminal domain (amino acids 325-486) facilitates binding to DNA [86] and it most likely increases protein stability [87]. This domain also contains conserved poly-proline motifs that can bind to group II WW domain splicing factors [88].

3.6. MeCP2 function

The original model suggested that MeCP2 is a global transcriptional repressor [89], and it was based on in vitro experiments in which MeCP2 inhibited transcription from methylated promoters. Briefly, the protein binds to the promoters of target genes via its MBD, and the TRD then recruits the co-repressor Sin3A and HDACs [90, 91]. These interactions lead to the deacetylation of histones, resulting in chromatin condensation and the repression of downstream genes. In addition to Sin3A, other co-repressors, such as c-Ski and N-CoR, may interact with MeCP2 [92]. The compaction of chromatin can also be promoted through direct interaction with the C-terminal domain [93], which is an example of HDAC-independent MeCP2-mediated transcriptional repression. The TRD may also directly interact with transcription factor IIB; therefore, MeCP2 may silence transcription by interfering with the assembly of the transcriptional preinitiation complex [94]. Additional factors interacting with the TRD include Brahma, which is a catalytic component of the SWI/SNF-related chromatin-remodeling complex (at least in NIH 3T3 cells) [95], DNA methyltransferase 1 [96], and ATRX, a SWI2/SNF2 DNA helicase/ATPase [97].

Surprisingly, transcriptional profiling studies did not reveal major gene expression changes caused by the lack of functional MeCP2 protein [98, 99]. These observations, together with additional evidence, implied that MeCP2 regulates the transcription of tissue-specific genes in specific brain regions during certain developmental stages instead of acting as a global repressor [98, 100-102]. However, recent studies suggest that MeCP2 reduces genome-wide transcriptional noise, potentially by repressing spurious transcription of repetitive elements [103, 104]. Surprisingly, MeCP2 also interacts with the transcriptional activator CREB, and its genomic distribution is often associated with actively transcribed genes [105, 106]. MeCP2 apparently has dual roles in transcriptional regulation as a repressor and as an activator, and it performs different downstream responses depending on the context.

MeCP2 additionally acts as an architectural chromatin protein that is involved in chromatin remodeling and nucleosome clustering, which is consistent with the fact that the majority of MeCP2-binding sites are located outside of genes [105, 107]. MeCP2 can bind in vitro to chromatin fibers and compact them into higher order structures [93, 108, 109].

For further complexity, MeCP2 may also be involved in RNA splicing. Its interaction with the RNA-binding protein Y box-binding protein 1 (YB-1) has been observed, and MeCP2-deficient mice showed aberrant alternative splicing patterns [110].

MeCP2 functions are undeniably much more complex than initially anticipated (Figure 3), although the precise mechanisms of their regulation remain unknown.

Figure 3.

Representation of multiple MeCP2 roles [111].

3.7. MeCP2 target genes

A comprehensive knowledge of the target genes that are controlled by MeCP2 is essential for understanding the pathomechanisms of Rett syndrome and subsequently developing effective therapeutic strategies. Multiple studies have attempted to identify genes with altered expression in neuronal and nonneuronal tissues from Rett syndrome patients and mouse models, but these studies have often yielded conflicting results [102, 106, 112, 113]. Nevertheless, several candidate target genes have been proposed (Table 2). One of the most extensively studied target genes is the brain-derived neurotrophic factor gene (Bdnf), which has been shown to be up and down regulated in an activity-dependent manner through MeCP2 phosphorylation in mice [113-115]. Other targets, such as the imprinted genes Dlx5 and Dlx6, also revealed a novel mode of gene repression mediated by MeCP2 through the formation of a silent chromatin loop (Figure 3) [116, 117].

Gene Function Reference
UBE3A member of ubiquitin proteasome pathway, transcriptional co-activator [118]
GABRB3 neurotransmission (GABA-A receptor) [118]
PCDHB1 cell adhesion [119]
PCDH7 cell adhesion [119]
Bdnf neuronal development and survival, neuronal plasticity, learning and memory (brain derived neurotropic factor) [113, 114]
Dlx5 neuronal transcription factor (probably involved in control of GABAergic differentiation) [116]
Sgk1 hormone signaling (regulation of renal functions and blood pressure) [120]
Fkbp5 hormone signaling (regulation of glucocorticoid receptor sensitivity) [120]
Uqcrc1 member of mitochondrial respiratory chain [121]
ID1, ID2, ID3, ID4 transcription factors (involved in cell differentiation and neural development) [122]
FXYD1 ion channel regulator [123]
IGFBP3 hormone signaling (regulation of cell proliferation and apoptosis) [124]
GDI1 regulation of GDP/GTP exchange [112]
APLP1 enhancer of neuronal apoptosis [112]
CLU Extracellular molecular chaperone [112]
Crh neuropeptide (regulation of neuroendocrine stress response) [125]

Table 2.

Some of MeCP2 target genes.

3.8. The effect of MECP2 mutations on MeCP2 function

Mutations in the MECP2 gene are not likely to act in a dominant-negative mechanism because only one allele is active in each female cell due to XCI. The functional consequences of missense mutations on the function of the MeCP2 protein are sometimes especially difficult to predict. This difficulty is because testing the protein’s various functions can be problematic because there are still many MeCP2 roles that are as yet unknown or not fully understood. Generally, mutations in the NLS prevent the transportation of the protein to the nucleus. Mutations located within the MBD reduce the affinity of the protein for methylated DNA [87, 126]. However, several mutant proteins with mutations in the MBD have been shown to bind to heterochromatin [127]. Proteins with an intact MBD but with a mutated TRD retain their ability to bind to methylated DNA, but they have impaired repressing activity [87]. Other mutations may affect the stability or the structure (secondary or tertiary) of the protein, and they may interfere with other functions of the protein.

3.9. Genotype-phenotype correlation

The severity of the clinical manifestations in Rett syndrome patients is widely variable and is relevant beyond the context of classic vs. atypical variants. Therefore, much effort has been devoted to uncovering the relationships between various MECP2 mutations and the variability of clinical features. Such knowledge may provide information on the likely clinical profile of new cases with specific MECP2 mutations and may be useful in designing specific preventive therapeutic interventions.

The general genotype-phenotype correlations were confirmed by numerous studies. As expected, patients with early truncating mutations (specifically p.R168X, p.R270X, p.R255X), large deletions of several exons, or the entire MECP2 gene usually have the most severe clinical presentations. A milder phenotype is often associated with late truncating mutations that do not affect the MBD or the TRD, such as p.R294X. Interestingly, late truncating mutations together with the missense mutation p.R133C, which is located in the MBD, are frequently detected in patients with a preserved speech variant of Rett syndrome [128-133].

Despite some overall trends, considerable variability in clinical severity is often observed among patients with the same MECP2 mutation [128, 130, 134]. Such variations may be caused by a different XCI pattern. Favorable skewing of XCI has been observed in some patients with milder phenotypes [135-137] and in asymptomatic carrier mothers [58, 135, 138]. However, XCI cannot be used as the single predictor because, according to several studies, it has limitations in explaining all of the differences of Rett syndrome severity [139-141]. Other modulation factors have been considered, such as BDNF [142, 143] and APOE [144].

3.10. Genetic counseling

A negative result from the MECP2 analysis (usually including analysis of the entire coding region and copy number analysis of large deletions/duplications) does not rule out the diagnosis of Rett syndrome because regulatory and non-coding regions are not routinely analyzed. The recurrence risk in a family with a single Rett syndrome case and an otherwise negative family history is very low (less than 0.5%) because the majority of MECP2 mutations arise de novo. Mothers of the patients, however, should be tested for MECP2 mutations found in their daughters to rule out the possibility of being asymptomatic carriers. In such case, the recurrence risk is 50%. Prenatal diagnosis may be performed even in pregnancies of non-carrier mothers due to the likelihood of germline mosaicism.


4. Management of Rett syndrome

Currently, there is no effective cure for Rett syndrome. However, hopes for developing a targeted therapy have risen following the announcement of a study that rescued the pathological phenotype in a mouse model after postnatal reactivation of Mecp2 [145, 146]. Treatment strategies are currently symptomatic and preventive. These strategies are aimed at ameliorating specific symptoms, such as seizures, mood disturbances, sleeping and feeding problems, as well as maintaining and improving motor and communication functions.

Rehabilitation programs and physical therapy help to control and improve balance and movement, maintain flexibility and strengthen muscles. These programs should be adapted to the patient’s individual state and needs. Proper physical therapy is also important for preventing joint contractures and other deformities, such as scoliosis. Occupational therapy is recommended for improving purposeful hand use and to attenuate stereotypic hand movements. Particular care should be taken to preserve and maintain alternative communication (eye contact, eye pointing, facial expressions, signs, etc.) and thereby improving social interactions. Receiving necessary nutrients and maintaining an adequate weight may result in improved growth. To ensure appropriate caloric and nutritional intake, a high-fat, high-calorie diet or gastrostomy feeding may be required. Sufficient intake of fluid and high-fiber food is necessary to prevent constipation. The patients with cardiac conduction defects (such as prolonged QTc intervals) should avoid certain medications, which may worsen the condition. These medications include several antipsychotics (thioridazine, tricyclic antidepressants), certain antiarrhythmics (quinidine, sotalol, amiodarone), and antibiotics (erythromycin) [147].

Early diagnosis and intervention, together with life-long management focused on each patient’s specific needs, can significantly improve the health, quality of life, and longevity of patients with Rett syndrome.


5. Conclusion

Much progress has been made in the identification of the multiple roles of the MeCP2 protein in the brain since its discovery. Nevertheless, many mysteries still remain in understanding the precise mechanisms of how MECP2 mutations affect protein function and subsequently contribute to the pathogenesis of Rett syndrome. A significant phenotypic overlap between Rett syndrome and several neurodevelopmental disorders implies that a common pathogenic process may induce or at least contribute to these conditions. The identification of pathogenic MECP2 mutations in a portion of patients without the classic Rett syndrome phenotype strengthens this theory. Understanding the molecular pathology underlying Rett syndrome will therefore shed more light on the role of epigenetic modifications in neuronal development and function, and it may provide insight into the pathogenesis of other neurodevelopmental disorders.



I would like to thank prof. Pavel Martasek, MD, Ph.D. for helpful discussions and critical reading of the manuscript. The author was supported by grants NT 13120-4/2012, MZCR RVO-VFN64165/2012, P24/LF1/3, and UNCE 204011/2012.


  1. 1. Rett A. [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. Wiener Medizinische Wochenschrift 1966;116(37): 723-6.
  2. 2. Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Annals of Neurology 1983;14(4): 471-9.
  3. 3. Hagberg B, Goutieres F, Hanefeld F, Rett A, Wilson J. Rett syndrome: criteria for inclusion and exclusion. Brain and Development 1985;7(3): 372-3.
  4. 4. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature Genetics 1999;23(2): 185-8.
  5. 5. Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. European Journal of Paediatric Neurology 2002;6(5): 293-7.
  6. 6. Laurvick CL, de Klerk N, Bower C, Christodoulou J, Ravine D, Ellaway C, et al. Rett syndrome in Australia: a review of the epidemiology. Journal of Pediatrics 2006;148(3): 347-52.
  7. 7. Ellaway C, Christodoulou J. Rett syndrome: clinical update and review of recent genetic advances. Journal of Paediatrics and Child Health 1999;35(5): 419-26.
  8. 8. Kerr AM. Early clinical signs in the Rett disorder. Neuropediatrics 1995;26(2): 67-71.
  9. 9. Burford B, Kerr AM, Macleod HA. Nurse recognition of early deviation in development in home videos of infants with Rett disorder. Journal of Intellectual Disability Research 2003;47(Pt 8): 588-96.
  10. 10. Einspieler C, Kerr AM, Prechtl HF. Abnormal general movements in girls with Rett disorder: the first four months of life. Brain and Development 2005;27 Suppl 1: S8-S13.
  11. 11. Smeets EE, Pelc K, Dan B. Rett Syndrome. Molecular Syndromology 2011;2(3-5): 113-27.
  12. 12. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007;56(3): 422-37.
  13. 13. Nomura Y, Segawa M. Natural history of Rett syndrome. Journal of Child Neurology 2005;20(9): 764-8.
  14. 14. Shahbazian MD, Zoghbi HY. Rett syndrome and MeCP2: linking epigenetics and neuronal function. American Journal of Human Genetics 2002;71(6): 1259-72.
  15. 15. Nomura Y. Early behavior characteristics and sleep disturbance in Rett syndrome. Brain and Development 2005;27 Suppl 1: S35-S42.
  16. 16. Nomura Y, Segawa M. Motor symptoms of the Rett syndrome: abnormal muscle tone, posture, locomotion and stereotyped movement. Brain and Development 1992;14 Suppl: S21-8.
  17. 17. Hagberg B. Rett syndrome: clinical peculiarities and biological mysteries. Acta Paediatrica 1995;84(9): 971-6.
  18. 18. Glaze DG, Frost JD, Jr., Zoghbi HY, Percy AK. Rett's syndrome. Correlation of electroencephalographic characteristics with clinical staging. Archives of Neurology 1987;44(10): 1053-6.
  19. 19. Steffenburg U, Hagberg G, Hagberg B. Epilepsy in a representative series of Rett syndrome. Acta Paediatrica 2001;90(1): 34-9.
  20. 20. Jian L, Nagarajan L, de Klerk N, Ravine D, Bower C, Anderson A, et al. Predictors of seizure onset in Rett syndrome. Journal of Pediatrics 2006;149(4): 542-7.
  21. 21. Witt Engerstrom I. Age-related occurrence of signs and symptoms in the Rett syndrome. Brain and Development 1992;14 Suppl: S11-20.
  22. 22. Mount RH, Hastings RP, Reilly S, Cass H, Charman T. Behavioural and emotional features in Rett syndrome. Disability and Rehabilitation 2001;23(3-4): 129-38.
  23. 23. Hagberg B, Witt-Engerstrom I. Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence. American Journal of Medical Genetics Suppl 1986;1: 47-59.
  24. 24. Roze E, Cochen V, Sangla S, Bienvenu T, Roubergue A, Leu-Semenescu S, et al. Rett syndrome: an overlooked diagnosis in women with stereotypic hand movements, psychomotor retardation, Parkinsonism, and dystonia? Movement Disorders 2007;22(3): 387-9.
  25. 25. Kerr AM, Armstrong DD, Prescott RJ, Doyle D, Kearney DL. Rett syndrome: analysis of deaths in the British survey. European Child & Adolescent Psychiatry 1997;6 Suppl 1: 71-4.
  26. 26. Guideri F, Acampa M, Hayek G, Zappella M, Di Perri T. Reduced heart rate variability in patients affected with Rett syndrome. A possible explanation for sudden death. Neuropediatrics 1999;30(3): 146-8.
  27. 27. Kerr AM, Julu PO. Recent insights into hyperventilation from the study of Rett syndrome. Archives of Disease in Childhood 1999;80(4): 384-7.
  28. 28. Holm VA. Physical growth and development in patients with Rett syndrome. American Journal of Medical Genetics Suppl 1986;1: 119-26.
  29. 29. Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Annals of Neurology 2010;68(6): 944-50.
  30. 30. Hagberg B. Clinical manifestations and stages of Rett syndrome. Mental Retardation and Developmental Disabilities Research Reviews 2002;8(2): 61-5.
  31. 31. Zappella M. The Rett girls with preserved speech. Brain and Development 1992;14(2): 98-101.
  32. 32. Hanefeld F. The clinical pattern of the Rett syndrome. Brain and Development 1985;7(3): 320-5.
  33. 33. Hagberg BA, Skjeldal OH. Rett variants: a suggested model for inclusion criteria. Pediatric Neurology 1994;11(1): 5-11.
  34. 34. Tao J, Van Esch H, Hagedorn-Greiwe M, Hoffmann K, Moser B, Raynaud M, et al. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. American Journal of Human Genetics 2004;75(6): 1149-54.
  35. 35. Ariani F, Hayek G, Rondinella D, Artuso R, Mencarelli MA, Spanhol-Rosseto A, et al. FOXG1 is responsible for the congenital variant of Rett syndrome. American Journal of Human Genetics 2008;83(1): 89-93.
  36. 36. Killian W. On the genetics of Rett syndrome: analysis of family and pedigree data. American Journal of Medical Genetics Suppl 1986;1: 369-76.
  37. 37. D'Esposito M, Quaderi NA, Ciccodicola A, Bruni P, Esposito T, D'Urso M, et al. Isolation, physical mapping, and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mammalian Genome 1996;7(7): 533-5.
  38. 38. Sirianni N, Naidu S, Pereira J, Pillotto RF, Hoffman EP. Rett syndrome: confirmation of X-linked dominant inheritance, and localization of the gene to Xq28. American Journal of Human Genetics 1998;63(5): 1552-8.
  39. 39. Coy JF, Sedlacek Z, Bachner D, Delius H, Poustka A. A complex pattern of evolutionary conservation and alternative polyadenylation within the long 3"-untranslated region of the methyl-CpG-binding protein 2 gene (MeCP2) suggests a regulatory role in gene expression. Human Molecular Genetics 1999;8(7): 1253-62.
  40. 40. Reichwald K, Thiesen J, Wiehe T, Weitzel J, Poustka WA, Rosenthal A, et al. Comparative sequence analysis of the MECP2-locus in human and mouse reveals new transcribed regions. Mammalian Genome 2000;11(3): 182-90.
  41. 41. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Human Molecular Genetics 2002;11(2): 115-24.
  42. 42. Pelka GJ, Watson CM, Christodoulou J, Tam PP. Distinct expression profiles of Mecp2 transcripts with different lengths of 3'UTR in the brain and visceral organs during mouse development. Genomics 2005;85(4): 441-52.
  43. 43. Santos M, Yan J, Temudo T, Oliveira G, Vieira JP, Fen J, et al. Analysis of highly conserved regions of the 3'UTR of MECP2 gene in patients with clinical diagnosis of Rett syndrome and other disorders associated with mental retardation. Disease Markers 2008;24(6): 319-24.
  44. 44. Percy AK. Rett syndrome: recent research progress. Journal of Child Neurology 2008;23(5): 543-9.
  45. 45. Psoni S, Sofocleous C, Traeger-Synodinos J, Kitsiou-Tzeli S, Kanavakis E, Fryssira-Kanioura H. MECP2 mutations and clinical correlations in Greek children with Rett syndrome and associated neurodevelopmental disorders. Brain and Development 2012;34(6): 487-95.
  46. 46. Raizis AM, Saleem M, MacKay R, George PM. Spectrum of MECP2 mutations in New Zealand Rett syndrome patients. The New Zealand Medical Journal 2009;122(1296): 21-8.
  47. 47. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. Human Gene Mutation Database (HGMD): 2003 update. Human Mutation 2003;21(6): 577-81.
  48. 48. Girard M, Couvert P, Carrie A, Tardieu M, Chelly J, Beldjord C, et al. Parental origin of de novo MECP2 mutations in Rett syndrome. European Journal of Human Genetics 2001;9(3): 231-6.
  49. 49. Trappe R, Laccone F, Cobilanschi J, Meins M, Huppke P, Hanefeld F, et al. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. American Journal of Human Genetics 2001;68(5): 1093-101.
  50. 50. Knudsen GP, Neilson TC, Pedersen J, Kerr A, Schwartz M, Hulten M, et al. Increased skewing of X chromosome inactivation in Rett syndrome patients and their mothers. European Journal of Human Genetics 2006;14(11): 1189-94.
  51. 51. Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, et al. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. American Journal of Human Genetics 1999;65(6): 1520-9.
  52. 52. Mari F, Caselli R, Russo S, Cogliati F, Ariani F, Longo I, et al. Germline mosaicism in Rett syndrome identified by prenatal diagnosis. Clinical Genetics 2005;67(3): 258-60.
  53. 53. Lee SS, Wan M, Francke U. Spectrum of MECP2 mutations in Rett syndrome. Brain and Development 2001;23 Suppl 1: S138-43.
  54. 54. Villard L. MECP2 mutations in males. Journal of Medical Genetics 2007;44(7): 417-23.
  55. 55. Schwartzman JS, Bernardino A, Nishimura A, Gomes RR, Zatz M. Rett syndrome in a boy with a 47,XXY karyotype confirmed by a rare mutation in the MECP2 gene. Neuropediatrics 2001;32(3): 162-4.
  56. 56. Armstrong J, Pineda M, Aibar E, Gean E, Monros E. Classic Rett syndrome in a boy as a result of somatic mosaicism for a MECP2 mutation. Annals of Neurology 2001;50(5): 692.
  57. 57. Pieras JI, Munoz-Cabello B, Borrego S, Marcos I, Sanchez J, Madruga M, et al. Somatic mosaicism for Y120X mutation in the MECP2 gene causes atypical Rett syndrome in a male. Brain and Development 2011;33(7): 608-11.
  58. 58. Villard L, Kpebe A, Cardoso C, Chelly PJ, Tardieu PM, Fontes M. Two affected boys in a Rett syndrome family: clinical and molecular findings. Neurology 2000;55(8): 1188-93.
  59. 59. Geerdink N, Rotteveel JJ, Lammens M, Sistermans EA, Heikens GT, Gabreels FJ, et al. MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings. Neuropediatrics 2002;33(1): 33-6.
  60. 60. Lundvall M, Samuelsson L, Kyllerman M. Male Rett phenotypes in T158M and R294X MeCP2-mutations. Neuropediatrics 2006;37(5): 296-301.
  61. 61. Moog U, Smeets EE, van Roozendaal KE, Schoenmakers S, Herbergs J, Schoonbrood-Lenssen AM, et al. Neurodevelopmental disorders in males related to the gene causing Rett syndrome in females (MECP2). European Journal of Paediatric Neurology 2003;7(1): 5-12.
  62. 62. Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K, et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. American Journal of Human Genetics 2005;77(3): 442-53.
  63. 63. Van Esch H. MECP2 Duplication Syndrome. Molecular Syndromology 2012;2(3-5): 128-36.
  64. 64. Ramocki MB, Tavyev YJ, Peters SU. The MECP2 duplication syndrome. American Journal of Medical Genetics Part A 2010;152A(5): 1079-88.
  65. 65. Lam CW, Yeung WL, Ko CH, Poon PM, Tong SF, Chan KY, et al. Spectrum of mutations in the MECP2 gene in patients with infantile autism and Rett syndrome. Journal of Medical Genetics 2000;37(12): E41.
  66. 66. Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A, Cuccaro ML, et al. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatric Neurology 2003;28(3): 205-11.
  67. 67. Watson P, Black G, Ramsden S, Barrow M, Super M, Kerr B, et al. Angelman syndrome phenotype associated with mutations in MECP2, a gene encoding a methyl CpG binding protein. Journal of Medical Genetics 2001;38(4): 224-8.
  68. 68. Milani D, Pantaleoni C, D'Arrigo S, Selicorni A, Riva D. Another patient with MECP2 mutation without classic Rett syndrome phenotype. Pediatric Neurology 2005;32(5): 355-7.
  69. 69. LaSalle JM, Goldstine J, Balmer D, Greco CM. Quantitative localization of heterogeneous methyl-CpG-binding protein 2 (MeCP2) expression phenotypes in normal and Rett syndrome brain by laser scanning cytometry. Human Molecular Genetics 2001;10(17): 1729-40.
  70. 70. Cohen DR, Matarazzo V, Palmer AM, Tu Y, Jeon OH, Pevsner J, et al. Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis. Molecular and Cellular Neuroscience 2003;22(4): 417-29.
  71. 71. Jung BP, Jugloff DG, Zhang G, Logan R, Brown S, Eubanks JH. The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells. Journal of Neurobiology 2003;55(1): 86-96.
  72. 72. Samaco RC, Nagarajan RP, Braunschweig D, LaSalle JM. Multiple pathways regulate MeCP2 expression in normal brain development and exhibit defects in autism-spectrum disorders. Human Molecular Genetics 2004;13(6): 629-39.
  73. 73. Kishi N, Macklis JD. Dissecting MECP2 function in the central nervous system. Journal of Child Neurology 2005;20(9): 753-9.
  74. 74. Smrt RD, Eaves-Egenes J, Barkho BZ, Santistevan NJ, Zhao C, Aimone JB, et al. Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiology of Disease 2007;27(1): 77-89.
  75. 75. Swanberg SE, Nagarajan RP, Peddada S, Yasui DH, LaSalle JM. Reciprocal co-regulation of EGR2 and MECP2 is disrupted in Rett syndrome and autism. Human Molecular Genetics 2009;18(3): 525-34.
  76. 76. Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ, et al. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nature Genetics 2004;36(4): 339-41.
  77. 77. Dragich JM, Kim YH, Arnold AP, Schanen NC. Differential distribution of the MeCP2 splice variants in the postnatal mouse brain. The Journal of Comparative Neurology 2007;501(4): 526-42.
  78. 78. Kriaucionis S, Bird A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Research 2004;32(5): 1818-23.
  79. 79. Itoh M, Tahimic CG, Ide S, Otsuki A, Sasaoka T, Noguchi S, et al. Methyl CpG-binding protein isoform MeCP2_e2 is dispensable for Rett syndrome phenotypes but essential for embryo viability and placenta development. The Journal of Biological Chemistry 2012;287(17): 13859-67.
  80. 80. Dastidar SG, Bardai FH, Ma C, Price V, Rawat V, Verma P, et al. Isoform-specific toxicity of Mecp2 in postmitotic neurons: suppression of neurotoxicity by FoxG1. Journal of Neuroscience 2012;32(8): 2846-55.
  81. 81. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F, et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992;69(6): 905-14.
  82. 82. Nan X, Meehan RR, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Research 1993;21(21): 4886-92.
  83. 83. Klose RJ, Sarraf SA, Schmiedeberg L, McDermott SM, Stancheva I, Bird AP. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Molecular Cell 2005;19(5): 667-78.
  84. 84. Galvao TC, Thomas JO. Structure-specific binding of MeCP2 to four-way junction DNA through its methyl CpG-binding domain. Nucleic Acids Research 2005;33(20): 6603-9.
  85. 85. Nan X, Tate P, Li E, Bird A. DNA methylation specifies chromosomal localization of MeCP2. Molecular and Cellular Biology 1996;16(1): 414-21.
  86. 86. Chandler SP, Guschin D, Landsberger N, Wolffe AP. The methyl-CpG binding transcriptional repressor MeCP2 stably associates with nucleosomal DNA. Biochemistry 1999;38(22): 7008-18.
  87. 87. Yusufzai TM, Wolffe AP. Functional consequences of Rett syndrome mutations on human MeCP2. Nucleic Acids Research 2000;28(21): 4172-9.
  88. 88. Buschdorf JP, Stratling WH. A WW domain binding region in methyl-CpG-binding protein MeCP2: impact on Rett syndrome. Journal of Molecular Medicine 2004;82(2): 135-43.
  89. 89. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997;88(4): 471-81.
  90. 90. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genetics 1998;19(2): 187-91.
  91. 91. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393(6683): 386-9.
  92. 92. Kokura K, Kaul SC, Wadhwa R, Nomura T, Khan MM, Shinagawa T, et al. The Ski protein family is required for MeCP2-mediated transcriptional repression. The Journal of Biological Chemistry 2001;276(36): 34115-21.
  93. 93. Nikitina T, Shi X, Ghosh RP, Horowitz-Scherer RA, Hansen JC, Woodcock CL. Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. Molecular and Cellular Biology 2007;27(3): 864-77.
  94. 94. Kaludov NK, Wolffe AP. MeCP2 driven transcriptional repression in vitro: selectivity for methylated DNA, action at a distance and contacts with the basal transcription machinery. Nucleic Acids Research 2000;28(9): 1921-8.
  95. 95. Harikrishnan KN, Chow MZ, Baker EK, Pal S, Bassal S, Brasacchio D, et al. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nature Genetics 2005;37(3): 254-64.
  96. 96. Kimura H, Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. The Journal of Biological Chemistry 2003;278(7): 4806-12.
  97. 97. Nan X, Hou J, Maclean A, Nasir J, Lafuente MJ, Shu X, et al. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proceedings of the National Academy of Sciences of the United States of America 2007;104(8): 2709-14.
  98. 98. Tudor M, Akbarian S, Chen RZ, Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proceedings of the National Academy of Sciences of the United States of America 2002;99(24): 15536-41.
  99. 99. Traynor J, Agarwal P, Lazzeroni L, Francke U. Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Medical Genetics 2002;3: 12.
  100. 100. Colantuoni C, Jeon OH, Hyder K, Chenchik A, Khimani AH, Narayanan V, et al. Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. Neurobiology of Disease 2001;8(5): 847-65.
  101. 101. Ballestar E, Ropero S, Alaminos M, Armstrong J, Setien F, Agrelo R, et al. The impact of MECP2 mutations in the expression patterns of Rett syndrome patients. Human Genetics 2005;116(1-2): 91-104.
  102. 102. Jordan C, Li HH, Kwan HC, Francke U. Cerebellar gene expression profiles of mouse models for Rett syndrome reveal novel MeCP2 targets. BMC Medical Genetics 2007;8: 36.
  103. 103. Muotri AR, Marchetto MC, Coufal NG, Oefner R, Yeo G, Nakashima K, et al. L1 retrotransposition in neurons is modulated by MeCP2. Nature 2010;468(7322): 443-6.
  104. 104. Skene PJ, Illingworth RS, Webb S, Kerr AR, James KD, Turner DJ, et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Molecular Cell 2010;37(4): 457-68.
  105. 105. Yasui DH, Peddada S, Bieda MC, Vallero RO, Hogart A, Nagarajan RP, et al. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proceedings of the National Academy Sciences of the United States of America 2007;104(49): 19416-21.
  106. 106. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008;320(5880): 1224-9.
  107. 107. Hite KC, Adams VH, Hansen JC. Recent advances in MeCP2 structure and function. Biochemistry and Cell Biology 2009;87(1): 219-27.
  108. 108. Georgel PT, Horowitz-Scherer RA, Adkins N, Woodcock CL, Wade PA, Hansen JC. Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. The Journal of Biological Chemistry 2003;278(34): 32181-8.
  109. 109. Nikitina T, Ghosh RP, Horowitz-Scherer RA, Hansen JC, Grigoryev SA, Woodcock CL. MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome. The Journal of Biological Chemistry 2007;282(38): 28237-45.
  110. 110. Young JI, Hong EP, Castle JC, Crespo-Barreto J, Bowman AB, Rose MF, et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proceeding of the National Academy of Sciences of the United States of America 2005;102(49): 17551-8.
  111. 111. Zachariah RM, Rastegar M. Linking epigenetics to human disease and Rett syndrome: the emerging novel and challenging concepts in MeCP2 research. Neural Plasticity 2012;2012: 415825.
  112. 112. Gibson JH, Slobedman B, K NH, Williamson SL, Minchenko D, El-Osta A, et al. Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain. BMC Neuroscience 2010;11: 53.
  113. 113. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003;302(5646): 890-3.
  114. 114. Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003;302(5646): 885-9.
  115. 115. Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY, Schmidt L, et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006;52(2): 255-69.
  116. 116. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nature Genetics 2005;37(1): 31-40.
  117. 117. Miyano M, Horike S, Cai S, Oshimura M, Kohwi-Shigematsu T. DLX5 expression is monoallelic and Dlx5 is up-regulated in the Mecp2-null frontal cortex. Journal of Cellular and Molecular Medicine 2008;12(4): 1188-91.
  118. 118. Samaco RC, Hogart A, LaSalle JM. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Human Molecular Genetics 2005;14(4): 483-92.
  119. 119. Miyake K, Hirasawa T, Soutome M, Itoh M, Goto Y, Endoh K, et al. The protocadherins, PCDHB1 and PCDH7, are regulated by MeCP2 in neuronal cells and brain tissues: implication for pathogenesis of Rett syndrome. BMC Neuroscience 2011;12: 81.
  120. 120. Nuber UA, Kriaucionis S, Roloff TC, Guy J, Selfridge J, Steinhoff C, et al. Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Human Molecular Genetics 2005;14(15): 2247-56.
  121. 121. Huppke P, Gartner J. Molecular diagnosis of Rett syndrome. Journal of Child Neurology 2005;20(9): 732-6.
  122. 122. Peddada S, Yasui DH, LaSalle JM. Inhibitors of differentiation (ID1, ID2, ID3 and ID4) genes are neuronal targets of MeCP2 that are elevated in Rett syndrome. Human Molecular Genetics 2006;15(12): 2003-14.
  123. 123. Deng V, Matagne V, Banine F, Frerking M, Ohliger P, Budden S, et al. FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. Human Molecular Genetics 2007;16(6): 640-50.
  124. 124. Itoh M, Ide S, Takashima S, Kudo S, Nomura Y, Segawa M, et al. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains. Journal of Neuropathology & Experimental Neurology 2007;66(2): 117-23.
  125. 125. McGill BE, Bundle SF, Yaylaoglu MB, Carson JP, Thaller C, Zoghbi HY. Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome. Proceedings of the National Academy of Sciences of the United States of America 2006;103(48): 18267-72.
  126. 126. Ballestar E, Yusufzai TM, Wolffe AP. Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. Biochemistry 2000;39(24): 7100-6.
  127. 127. Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Hammer S, et al. Functional characterisation of MeCP2 mutations found in male patients with X linked mental retardation. Journal of Medical Genetics 2002;39(2): 132-6.
  128. 128. Bebbington A, Anderson A, Ravine D, Fyfe S, Pineda M, de Klerk N, et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology 2008;70(11): 868-75.
  129. 129. Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 2008;70(16): 1313-21.
  130. 130. Halbach NS, Smeets EE, van den Braak N, van Roozendaal KE, Blok RM, Schrander-Stumpel CT, et al. Genotype-phenotype relationships as prognosticators in Rett syndrome should be handled with care in clinical practice. American Journal of Medical Genetics Part A 2012;158A(2): 340-50.
  131. 131. Young D, Bebbington A, de Klerk N, Bower C, Nagarajan L, Leonard H. The relationship between MECP2 mutation type and health status and service use trajectories over time in a Rett syndrome population. Research in Autism Spectrum Disorders 2011;5(1): 442-9.
  132. 132. Bebbington A, Percy A, Christodoulou J, Ravine D, Ho G, Jacoby P, et al. Updating the profile of C-terminal MECP2 deletions in Rett syndrome. Journal of Medical Genetics 2010;47(4): 242-8.
  133. 133. Renieri A, Mari F, Mencarelli MA, Scala E, Ariani F, Longo I, et al. Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant). Brain and Development 2009;31(3): 208-16.
  134. 134. Scala E, Longo I, Ottimo F, Speciale C, Sampieri K, Katzaki E, et al. MECP2 deletions and genotype-phenotype correlation in Rett syndrome. American Journal of Medical Genetics Part A 2007;143A(23): 2775-84.
  135. 135. Hardwick SA, Reuter K, Williamson SL, Vasudevan V, Donald J, Slater K, et al. Delineation of large deletions of the MECP2 gene in Rett syndrome patients, including a familial case with a male proband. European Journal of Human Genetics 2007;15(12): 1218-29.
  136. 136. Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran CQ, Dahle EJ, et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Annals of Neurology 2000;47(5): 670-9.
  137. 137. Huppke P, Maier EM, Warnke A, Brendel C, Laccone F, Gartner J. Very mild cases of Rett syndrome with skewed X inactivation. Journal of Medical Genetics 2006;43(10): 814-6.
  138. 138. Villard L, Levy N, Xiang F, Kpebe A, Labelle V, Chevillard C, et al. Segregation of a totally skewed pattern of X chromosome inactivation in four familial cases of Rett syndrome without MECP2 mutation: implications for the disease. Journal of Medical Genetics 2001;38(7): 435-42.
  139. 139. Takahashi S, Ohinata J, Makita Y, Suzuki N, Araki A, Sasaki A, et al. Skewed X chromosome inactivation failed to explain the normal phenotype of a carrier female with MECP2 mutation resulting in Rett syndrome. Clinical Genetics 2008;73(3): 257-61.
  140. 140. Archer H, Evans J, Leonard H, Colvin L, Ravine D, Christodoulou J, et al. Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. Journal of Medical Genetics 2007;44(2): 148-52.
  141. 141. Xinhua B, Shengling J, Fuying S, Hong P, Meirong L, Wu XR. X chromosome inactivation in Rett Syndrome and its correlations with MECP2 mutations and phenotype. Journal of Child Neurology 2008;23(1): 22-5.
  142. 142. Zeev BB, Bebbington A, Ho G, Leonard H, de Klerk N, Gak E, et al. The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome. Neurology 2009;72(14): 1242-7.
  143. 143. Nectoux J, Bahi-Buisson N, Guellec I, Coste J, De Roux N, Rosas H, et al. The p.Val66Met polymorphism in the BDNF gene protects against early seizures in Rett syndrome. Neurology 2008;70(22 Pt 2): 2145-51.
  144. 144. Zahorakova D, Jachymova M, Kemlink D, Baxova A, Martasek P. APOE epsilon4: a potential modulation factor in Rett syndrome. Journal of Child Neurology 2010;25(5): 546-50.
  145. 145. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007;315(5815): 1143-7.
  146. 146. Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proceedings of the National Academy of Sciences of the United States of America 2007;104(6): 1931-6.
  147. 147. Ellaway CJ, Sholler G, Leonard H, Christodoulou J. Prolonged QT interval in Rett syndrome. Archives of Disease in Childhood 1999;80(5): 470-2.

Written By

Daniela Zahorakova

Submitted: 10 July 2012 Published: 17 April 2013